Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study

Trial Profile

Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Methionine enkephalin (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2010 Planned end date changed from 1 Jul 2008 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 02 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top